(VIRP) Virbac - Ratings and Ratios
Vaccines, Antibiotics, Parasiticides, Dermatology, Petfood
Description: VIRP Virbac
Virbac SA is a global animal health company that develops, manufactures, and markets a diverse range of products and services for companion and farm animals. The companys product portfolio includes vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, and nutrition products. Virbac serves veterinarians, farmers, and pet owners across multiple regions, including Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.
From a financial perspective, Virbacs market capitalization stands at approximately €3.05 billion, indicating a mid-cap company with a significant presence in the animal health industry. The companys return on equity (RoE) is 27.80%, suggesting a strong ability to generate profits from shareholder equity. With a price-to-earnings (P/E) ratio of 20.98, Virbacs stock is trading at a reasonable valuation relative to its earnings. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be analyzed. For instance, a stable or increasing gross margin could indicate effective pricing strategies and cost management.
To gain a deeper understanding of Virbacs competitive position, its essential to examine the companys research and development (R&D) pipeline, product launches, and market share trends. A strong R&D pipeline can drive future growth, while successful product launches can contribute to revenue increases. Additionally, analyzing Virbacs debt-to-equity ratio and interest coverage ratio can provide insights into the companys financial leverage and ability to meet its financial obligations. By examining these KPIs, investors can make more informed decisions about Virbacs stock.
VIRP Stock Overview
Market Cap in USD | 3,030m |
Sub-Industry | Pharmaceuticals |
IPO / Inception |
VIRP Stock Ratings
Growth Rating | 14.7% |
Fundamental | 86.2% |
Dividend Rating | 58.0% |
Return 12m vs S&P 500 | -30.1% |
Analyst Rating | - |
VIRP Dividends
Dividend Yield 12m | 0.47% |
Yield on Cost 5y | 0.69% |
Annual Growth 5y | 20.74% |
Payout Consistency | 82.1% |
Payout Ratio | 9.1% |
VIRP Growth Ratios
Growth Correlation 3m | -89.1% |
Growth Correlation 12m | 11.9% |
Growth Correlation 5y | 21.5% |
CAGR 5y | 9.44% |
CAGR/Max DD 3y (Calmar Ratio) | 0.32 |
CAGR/Mean DD 3y (Pain Ratio) | 0.84 |
Sharpe Ratio 12m | -1.73 |
Alpha | -22.57 |
Beta | 0.833 |
Volatility | 27.23% |
Current Volume | 4.1k |
Average Volume 20d | 3.6k |
Stop Loss | 301.6 (-3%) |
Signal | 0.43 |
Piotroski VR‑10 (Strict, 0-10) 9.5
Net Income (274.0m TTM) > 0 and > 6% of Revenue (6% = 166.3m TTM) |
FCFTA 0.10 (>2.0%) and ΔFCFTA 4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
NWC/Revenue 14.85% (prev 35.92%; Δ -21.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
CFO/TA 0.18 (>3.0%) and CFO 327.0m > Net Income 274.0m (YES >=105%, WARN >=100%) |
Net Debt (197.0m) to EBITDA (500.8m) ratio: 0.39 <= 3.0 (WARN <= 3.5) |
Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
Outstanding Shares last Quarter (8.38m) change vs 12m ago -0.93% (target <= -2.0% for YES) |
Gross Margin 66.56% (prev 33.87%; Δ 32.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
Asset Turnover 171.3% (prev 85.19%; Δ 86.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
Interest Coverage Ratio 19.01 (EBITDA TTM 500.8m / Interest Expense TTM 21.1m) >= 6 (WARN >= 3) |
Altman Z'' 4.78
(A) 0.23 = (Total Current Assets 842.2m - Total Current Liabilities 430.5m) / Total Assets 1.82b |
(B) 0.05 = Retained Earnings (Balance) 82.4m / Total Assets 1.82b |
(C) 0.25 = EBIT TTM 401.5m / Avg Total Assets 1.62b |
(D) 1.41 = Book Value of Equity 1.06b / Total Liabilities 750.3m |
Total Rating: 4.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.18
1. Piotroski 9.50pt = 4.50 |
2. FCF Yield 6.73% = 3.37 |
3. FCF Margin 6.79% = 1.70 |
4. Debt/Equity 0.31 = 2.45 |
5. Debt/Ebitda 0.39 = 2.38 |
6. ROIC - WACC (= 13.07)% = 12.50 |
7. RoE 27.38% = 2.28 |
8. Rev. Trend 92.29% = 6.92 |
9. EPS Trend 1.61% = 0.08 |
What is the price of VIRP shares?
Over the past week, the price has changed by -2.20%, over one month by -0.80%, over three months by -8.53% and over the past year by -19.69%.
Is Virbac a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VIRP is around 264.83 EUR . This means that VIRP is currently overvalued and has a potential downside of -14.85%.
Is VIRP a buy, sell or hold?
What are the forecasts/targets for the VIRP price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 396.3 | 27.4% |
Analysts Target Price | - | - |
ValueRay Target Price | 294.4 | -5.3% |
VIRP Fundamental Data Overview
Market Cap EUR = 2.60b (2.60b EUR * 1.0 EUR.EUR)
P/E Trailing = 19.5337
P/S = 1.8127
P/B = 2.5407
Beta = 0.833
Revenue TTM = 2.77b EUR
EBIT TTM = 401.5m EUR
EBITDA TTM = 500.8m EUR
Long Term Debt = 203.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 97.5m EUR (from shortTermDebt, last quarter)
Debt = 325.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 197.0m EUR (from netDebt column, last quarter)
Enterprise Value = 2.79b EUR (2.60b + Debt 325.6m - CCE 128.7m)
Interest Coverage Ratio = 19.01 (Ebit TTM 401.5m / Interest Expense TTM 21.1m)
FCF Yield = 6.73% (FCF TTM 188.2m / Enterprise Value 2.79b)
FCF Margin = 6.79% (FCF TTM 188.2m / Revenue TTM 2.77b)
Net Margin = 9.88% (Net Income TTM 274.0m / Revenue TTM 2.77b)
Gross Margin = 66.56% ((Revenue TTM 2.77b - Cost of Revenue TTM 927.1m) / Revenue TTM)
Gross Margin QoQ = 67.38% (prev 65.49%)
Tobins Q-Ratio = 1.54 (Enterprise Value 2.79b / Total Assets 1.82b)
Interest Expense / Debt = 1.54% (Interest Expense 5.00m / Debt 325.6m)
Taxrate = 33.68% (41.8m / 124.0m)
NOPAT = 266.3m (EBIT 401.5m * (1 - 33.68%))
Current Ratio = 1.96 (Total Current Assets 842.2m / Total Current Liabilities 430.5m)
Debt / Equity = 0.31 (Debt 325.6m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 0.39 (Net Debt 197.0m / EBITDA 500.8m)
Debt / FCF = 1.05 (Net Debt 197.0m / FCF TTM 188.2m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.09% (Net Income 274.0m / Total Assets 1.82b)
RoE = 27.38% (Net Income TTM 274.0m / Total Stockholder Equity 1.00b)
RoCE = 33.33% (EBIT 401.5m / Capital Employed (Equity 1.00b + L.T.Debt 203.9m))
RoIC = 21.25% (NOPAT 266.3m / Invested Capital 1.25b)
WACC = 8.18% (E(2.60b)/V(2.92b) * Re(9.08%) + D(325.6m)/V(2.92b) * Rd(1.54%) * (1-Tc(0.34)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.22%
[DCF Debug] Terminal Value 70.38% ; FCFE base≈144.5m ; Y1≈115.3m ; Y5≈77.9m
Fair Price DCF = 145.0 (DCF Value 1.21b / Shares Outstanding 8.38m; 5y FCF grow -24.16% → 3.0% )
EPS Correlation: 1.61 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 92.29 | Revenue CAGR: 20.26% | SUE: 1.06 | # QB: 1